<SEC-DOCUMENT>0001295345-16-000708.txt : 20161017
<SEC-HEADER>0001295345-16-000708.hdr.sgml : 20161017
<ACCEPTANCE-DATETIME>20161017130024
ACCESSION NUMBER:		0001295345-16-000708
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20161017
ITEM INFORMATION:		Termination of a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20161017
DATE AS OF CHANGE:		20161017

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Emerald Medical Applications Corp.
		CENTRAL INDEX KEY:			0000797542
		STANDARD INDUSTRIAL CLASSIFICATION:	BLANK CHECKS [6770]
		IRS NUMBER:				680080601
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-15746
		FILM NUMBER:		161938528

	BUSINESS ADDRESS:	
		STREET 1:		7 IMBER STREET
		CITY:			PETACH TIKVA
		STATE:			L3
		ZIP:			4951141
		BUSINESS PHONE:		97237444505

	MAIL ADDRESS:	
		STREET 1:		7 IMBER STREET
		CITY:			PETACH TIKVA
		STATE:			L3
		ZIP:			4951141

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ZAXIS INTERNATIONAL INC
		DATE OF NAME CHANGE:	19950916

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INFERGENE CO
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>mrla8k10172016.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<html>
<body>
<div>

<hr SIZE="4" NOSHADE COLOR="#000000">

<p ALIGN="CENTER"><font FACE="TIMES NEW ROMAN, TIMES, SERIF" SIZE="4"><b>UNITED STATES<br>
SECURITIES AND EXCHANGE COMMISSION<br>
</b></font></p>

<p ALIGN="CENTER"><b><font FACE="TIMES NEW ROMAN, TIMES, SERIF" SIZE="3">Washington, D.C.
20549<br>
</font></b></p>

<p ALIGN="CENTER"><font SIZE="4" FACE="Times New Roman, Times, Serif">___________________<br>
<br>
<strong>FORM 8-K<br>
</strong>___________________</font></p>

<p align="center"><font size="3"><b>CURRENT REPORT</b> </font></p>

<p align="center"><font size="2"><b>Pursuant to Section&nbsp;13 or 15(d) of the Securities
Exchange Act of 1934</b> </font></p>

<p align="center"><font size="2">Date of report (date of earliest event reported):
October 10, 2016</font></p>

<p align="center">&nbsp;</p>

<p ALIGN="CENTER"><font face="TIMES NEW ROMAN, TIMES, SERIF" size="5"><b><u>
EMERALD MEDICAL APPLICATIONS CORP.</u><br>
</b></font><font face="TIMES NEW ROMAN, TIMES, SERIF" size="1">(Exact Name of Registrant
as Specified in its Charter)</font></p>

<p ALIGN="CENTER">&nbsp;</p>

<p ALIGN="CENTER"><font size="2">Commission File No.: 0-15476</font></p>

<p ALIGN="CENTER">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" width="100%">
  <tr>
    <td width="50%" align="center" style="height: 1px"><font FACE="TIMES NEW ROMAN, TIMES, SERIF" SIZE="2"><u>Delaware</u></font></td>
    <td width="50%" align="center" style="height: 1px"><font FACE="TIMES NEW ROMAN, TIMES, SERIF" SIZE="2"><u>68-0080601</u></font></td>
  </tr>
  <tr>
    <td width="50%" align="center" bgcolor="#ffffff" style="height: 1px"><font size="1">(State of Incorporation)</font></td>
    <td width="50%" align="center" bgcolor="#ffffff" style="height: 1px"><font size="1">(I.R.S. Employer
    Identification No.)</font></td>
  </tr>
  <tr>
    <td width="50%" align="center" style="height: 1px"><font size="1">&nbsp; </font></td>
    <td width="50%" align="center" style="height: 1px"><font size="1">&nbsp; </font></td>
  </tr>
  <tr>
    <td width="50%" align="center" style="height: 1px">
	<font FACE="TIMES NEW ROMAN, TIMES, SERIF" SIZE="2"><u>7 Imber Street,
	Petach Tikva,
	Israel</u></font></td>
    <td width="50%" align="center" style="height: 1px">
	<font FACE="TIMES NEW ROMAN, TIMES, SERIF" SIZE="2"><u>4951141</u></font></td>
  </tr>
  <tr>
    <td width="50%" align="center" bgcolor="#ffffff" style="height: 1px"><font size="1">(Address of Principal
    Executive Offices)</font></td>
    <td width="50%" align="center" bgcolor="#ffffff" style="height: 1px"><font size="1">(ZIP Code)</font></td>
  </tr>
</table>

<p>&nbsp;</p>

<p ALIGN="CENTER"><font FACE="TIMES NEW ROMAN, TIMES, SERIF" SIZE="2">Registrant's
Telephone Number, including area code: (972) 3-744-4505</font></p>

<p ALIGN="CENTER">&nbsp;</p>

<p><font size="2">Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below): </font></p>

<p><font size="2" FACE="WINGDINGS">&#168</font><font size="2"> Written communications
pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425) <br>
</font><font size="2" FACE="WINGDINGS">&#168</font><font size="2"> Soliciting material
pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)<br>
</font><font size="2" FACE="WINGDINGS">&#168</font><font size="2"> Pre-commencement
communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<br>
</font><font size="2" FACE="WINGDINGS">&#168</font><font size="2"> Pre-commencement
communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
</font></p>


<p Style='page-break-before:always'>

<hr SIZE="2" NOSHADE COLOR="#000000">

	<p><b><font size="2">Item 1.02 Termination of a Material Definitive
	Agreement.</font></b></p>
	<p><font size="2">On May 18, 2016, Emerald Medical Applications Corp. (the
	&quot;Registrant&quot;) filed a Form 8-K reporting that on May 12, 2016, it had
	entered into an Equity Purchase Agreement and a Registration Rights
	Agreement with Kodiak Capital Group, LLC, a limited liability company
	organized under the laws of the State of Delaware with offices located in
	Newport Beach, CA (&quot;Kodiak&quot;). Under the Equity Purchase Agreement (the
	&quot;EPA&quot;), the Registrant: (i) agreed to issue and sell to Kodiak and Kodiak
	agreed to purchase up to $1,000,000 of the Registrant's common stock; (ii)
	issued Kodiak 150,000 restricted shares as a commitment fee; and (iii)
	executed a Registration Rights Agreement pursuant to which the Registrant
	has agreed to file a registration statement to register for resale the
	underlying the EPA and the 150,000 commitment shares.</font></p>
	<p><font size="2">On October 10, 2016, Emerald Medical Applications Corp.
	(the &quot;Registrant&quot;) served notice on Kodiak that it was: (i) terminating the
	EPA pursuant to Section 10.5 of that agreement; and (ii) amending the
	pending registration statement on Form S-1 that had been filed with the SEC
	on July 27, 2015 for the purpose of removing the shares underlying the EPA
	commitment as well as the commitment shares. A copy of the letter of
	termination is attached hereto as Exhibit 10.36.</font></p>
	<font size="2" FACE="Times New Roman">
	<p ALIGN="JUSTIFY"><strong>Item 9.01 Financial Statements and Exhibits</strong></p>

<p align="justify">(b) The following documents are filed as exhibits to
this current report or incorporated by reference herein. Any document
incorporated by reference is identified by a parenthetical reference to the SEC filing
that included such document.</p>

<table ALIGN="CENTER" CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="100%" height="0%">
  <tr VALIGN="BOTTOM">
    <th height="0" bgcolor="#ffffff" style="width: 7%; height: 0%"><p align="left">
	<font SIZE="2">Exhibit No.</font></th>
    <th ALIGN="LEFT" height="0" bgcolor="#ffffff" style="width: 93">
	<font SIZE="2">Description</font></th>
  </tr>
  <tr>
    <td bgcolor="#FFFFFF" height="0%" style="width: 7%; height: 0"><font SIZE="2">10.36</font></td>
    <td bgcolor="#FFFFFF" height="0%" style="width: 93%; height: 0">
	<font SIZE="2">Termination Letter to Kodiak Capital Group, LLC dated October
	10, 2016, filed herewith.</td>
  </tr>
</table>

	</font>
	<font size="2">
	<p style="text-align: center"><font size="2" face="Times New Roman">
	<font size="2">SIGNATURES</font></p>

<p ALIGN="JUSTIFY"><font size="2">Pursuant to the requirements of the Securities Exchange
Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.</font></p>

<table ALIGN="CENTER" CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="100%">
  <tr VALIGN="TOP" BGCOLOR="#66FFFF">
    <td ALIGN="LEFT" WIDTH="100%" bgcolor="#FFFFFF"><div
    STYLE="MARGIN-LEFT: 11px; TEXT-INDENT: -10px"><u><p><i><font
    face="TIMES NEW ROMAN, TIMES, SERIF" size="2">/s/ Adi Zamir</font></i></u><br>
    <font size="2">CEO<br>
    	Adi Zamir<br>
    <i>&nbsp;&nbsp;</i>Date: October 17, 2016</font></p>
    </div></td>
  </tr>
</table>

	</font>

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>2
<FILENAME>exh10_36.htm
<DESCRIPTION>EXHIBIT 10.36
<TEXT>
<html>
<body>

<p><center><img src="mrla_logo.jpg"></center>
<p><font size="2">7 Imber Street<br />
Petach Tikva, 4951141<br />
Israel<br />
October 10, 2016<br />
<br />
Kodiak Capital Group, LLC<br />
Attn: Ryan Hodson<br />
Managing Director<br />
260 Newport Center Drive<br />
Newport Beach, CA 92660<br />
<br />
Re: Notice of Termination<br />
Equity Purchase Agreement<br />
<br />
Dear Mr. Hodson:<br />
<br />
Please accept this letter as notice by Emerald Medical Applications Corp. (the
&quot;Company&quot;) of the termination of the Equity Purchase Agreement between the
Company and Kodiak Capital Group, LLC (&quot;Kodiak&quot;) dated May 12, 2016 (the &quot;EPA&quot;)
pursuant to Section 10.5 of the EPA. There are several reasons for our election
to terminate the EPA and amend the registration statement filed on July 27, 2016
(the &quot;Registration Statement&quot;) to remove the Put Shares issuable to Kodiak as
well as the Commitment Shares issued to Kodiak on May 18, 2016, including, among
other reasons, the following:<br />
<br />
In the SEC comment letter with respect to the Registration Statement, they
state:</font></p>
<p><font size="2">&quot;It appears that the Equity Purchase Agreement contains a provision that may
result in Kodiak Capital Group LLC not being irrevocably bound to purchase the
shares that you elect to put under the agreement. In this regard, Section 7.2(f)
of the Equity Purchase Agreement states that the obligation of an investor to
acquire and pay for Put Shares is conditioned on the fact that there has been no
suspension of trading in or delisting of your common stock.&quot;<br />
<br />
&quot;If Kodiak Capital Group LLC is not irrevocably bound to purchase the put
shares, you should: (i) amend your registration statement to eliminate the
shares to be issued pursuant to the Equity Purchase Agreement from your present
offering; or (ii) amend the Equity Purchase Agreement as appropriate and
register the shares to be issued pursuant to the Equity Purchase Agreement on a
new Form S-1.&quot;<br />
<br />
As a result of the SEC's statement that Kodiak is not irrevocably bound to
purchase the [put] shares, we are required to amend the Registration Statement
to eliminate the Kodiak Put Shares pursuant to the EPA. In the alternative, the
SEC stated that we can elect to amend the EPA &quot;as appropriate&quot; and register the
Put Shares on a new S-1. We are not willing to incur the expense and delay that
option (ii) above provides;<br />
(ii) As a result of the fact that the SEC deems that Kodiak is not irrevocably
bound to purchase the Put Shares, Kodiak's commitment in the EPA to do so is
conditional and not a binding commitment. Accordingly, the 150,000 Commitment
Shares that were issued to Kodiak on May 18, 2016, were issued for &quot;no
consideration&quot; and are, as a result, not &quot;fully-paid&quot; shares. Therefore, the
holding period under Rule 144(d) has not and will not &quot;run&quot; and the Commitment
Shares are not eligible for resale under Rule 144.<br />
<br />
Based upon the foregoing, we have determined not to proceed with the Kodiak EPA
and further demand the return of all of the 150,000 Commitment Shares within
five (5) business days of this letter of termination.<br />
<br />
Respectfully,<br />
<br />
/s/: Adi Zamir<br />
Adi Zamir, CEO<br />
</p>

</body>

</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>mrla_logo.jpg
<TEXT>
begin 644 mrla_logo.jpg
M_]C_X  02D9)1@ !  $ *0 7  #__@ ?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$  @&!@<&!0@'!P<*"0@*#18.#0P,#1L3%! 6(!PB(1\<
M'QXC*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3<!"0H*#0L-&@X.&C<D
M'R0W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W
M-S<W-S<W-__^ !X"     @    0   !:     P    0         _\0!H@
M 04! 0$! 0$           $" P0%!@<("0H+ 0 # 0$! 0$! 0$!
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M\O/T]?;W^/GZ_\  $0@ 0 'D P$1  (1 0,1 ?_:  P# 0 "$0,1 #\ ]_H
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M;W5R@),2DAB!U(! R/I0!!?_ !&\'Z7/=07OB"TAGM7\N6,L2ZMZ;0,GIVH
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MVQTC6OAW8Z=:0VEK%K"A(H4"J.G84 <Y\1;R\^'GCC5-4TZ)S%XGTUH$$?\
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MC<H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M92BX4XQ?1(M4&@4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0!DW.B"XN9IQ.R&25)-H'&5V[2?<;3^8]!3N!7_L.Z,:(]YOP
MP)W%N,$'(]SCOZ_F7 D;2;SR6C2[ 8D?O,MN/!QWP,<=.N*+@2OI4KQ6ZFX"
M&W)=-J\%MV03GVXX]31<"LNCWX"9N5&!\V)'/S?W^O7VZ<47 ECTFZB*[;E3
MMR%!W +P,$ 'D\=*+@,31;I=Q^U@.1C=DYP-V%SZ?-1<!_\ 8]QL8F[;>>
?[85<'Y1STR1S[47 U8$:.WB1V#.J@,1W.*0$E '_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
